Form 4: Cyclo Therapeutics Director Shawn Cross Receives Stock Grant in Lieu of Cash Compensation

Director Shawn Cross of Cyclo Therapeutics, Inc. received 9,028 shares of common stock on August 16, 2024, as compensation for the second quarter of 2024, in lieu of cash.

Summary

• On August 16, 2024, Shawn Cross, a director of Cyclo Therapeutics, Inc., acquired 9,028 shares of common stock.
• The shares were granted as compensation for the second quarter of 2024, in lieu of cash, under the company's non-employee director compensation policy.
• The price was calculated based on the closing price of $1.26 per share on August 16, 2024.
• Following the transaction, Cross directly owns 90,521 shares of Cyclo Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of director compensation. The director taking stock instead of cash is a slightly positive sign.

Positives

• The director's acceptance of stock in lieu of cash may signal confidence in the company's future prospects.

Industry Context

Director compensation in the form of stock grants is a common practice to align the interests of directors with those of shareholders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it demonstrates the director's confidence in the company.

Key Dates